- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Niederländisch
- Bibliographic citation
-
GLP-1-receptoragonisten en renoprotectie in type 2-diabetes ; volume:22 ; number:3 ; day:27 ; month:8 ; year:2024 ; pages:21-26 ; date:9.2024
Nederlands Tijdschrift voor Diabetologie ; 22, Heft 3 (27.8.2024), 21-26, 9.2024
- Classification
-
Medizin, Gesundheit
- Creator
-
H.A. Muskiet, Marcel
M. Apperloo, Ellen
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12467-024-1567-6
- URN
-
urn:nbn:de:101:1-2411130734094.187506150050
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- H.A. Muskiet, Marcel
- M. Apperloo, Ellen
- SpringerLink (Online service)
Other Objects (12)
GLP-1 - Therapiepotential bei Diabetes mellitus
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Type 2 diabetes is associated with impaired jejunal enteroendocrine GLP-1 cell lineage in human obesity
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes
Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
GLP-1 - Therapiepotential bei Diabetes mellitus
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Type 2 diabetes is associated with impaired jejunal enteroendocrine GLP-1 cell lineage in human obesity
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes
Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
GLP-1 - Therapiepotential bei Diabetes mellitus
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Type 2 diabetes is associated with impaired jejunal enteroendocrine GLP-1 cell lineage in human obesity
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes
Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective